{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T17:26:44Z","timestamp":1786728404551,"version":"build-2736575974"},"reference-count":53,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:p>Acute pain, moderate-to-severe cancer pain, and persistent malignant pain are all frequently treated with opioids. It is regarded as one of the main tenets of analgesic treatment. The relationship between human opioid sensitivity and genetic polymorphism differences has received little attention up to this point in research. Nonetheless, there is mounting proof that pharmacogenomic diversity could affect how each person reacts to opioids. Finding out how gene polymorphism affects analgesic use is the aim of this investigation, particularly opioids. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses standards were followed in the preparation of the systematic review approach used in this work. Oxycodone, fentanyl, raclopride, tramadol, ketorolac, morphine, ropivacaine, levobupivacaine, subfentanyl, remifentanil, and nortriptyline were the opioid medications used in the study, which was based on 13 publications. From those articles, we reviewed the impact of gene polymorphism on pain management and drug pharmacokinetics. Based on this systematic review, we concluded that gene polymorphism of gene affects analgesic, specifically opioid mechanisms.<\/jats:p>","DOI":"10.4103\/japtr.japtr_69_24","type":"journal-article","created":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T06:03:32Z","timestamp":1721628212000},"page":"135-138","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Gene polymorphism impact on opioid analgesic usage"],"prefix":"10.4103","volume":"15","author":[{"given":"Sry Suryani","family":"Widjaja","sequence":"first","affiliation":[{"name":"Department of Biochemistry, Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Ichwan","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Balram","family":"Chowbay","sequence":"additional","affiliation":[{"name":"Duke-NUS Medical School, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Rusdiana","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tengku Helvi","family":"Mardani","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vito Filbert","family":"Jayalie","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Universitas Imelda, Medan, Indonesia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,7,22]]},"reference":[{"key":"R1-20260507","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1056\/NEJMra1807054","article-title":"Prevention of opioid overdose","volume":"380","author":"Babu","year":"2019","journal-title":"N Engl J Med"},{"key":"R2-20260507","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s40122-022-00374-0","article-title":"Progress, challenges, and prospects of research on the effect of gene polymorphisms on adverse reactions to opioids","volume":"11","author":"Zhao","year":"2022","journal-title":"Pain Ther"},{"key":"R3-20260507","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1097\/FTD.0000000000000009","article-title":"Clinical pharmacokinetics of morphine and its metabolites during morphine dose titration for chronic cancer pain","volume":"36","author":"De Gregori","year":"2014","journal-title":"Ther Drug Monit"},{"key":"R4-20260507","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/ejp.970","article-title":"European pain federation position paper on appropriate opioid use in chronic pain management","volume":"21","author":"O\u2019Brien","year":"2017","journal-title":"Eur J Pain"},{"key":"R5-20260507","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1159\/000326085","article-title":"CYP2D6 in the metabolism of opioids for mild to moderate pain","volume":"87","author":"Leppert","year":"2011","journal-title":"Pharmacology"},{"key":"R6-20260507","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/bcp.13129","article-title":"A review of factors explaining variability in fentanyl pharmacokinetics; focus on implications for cancer patients","volume":"83","author":"Kuip","year":"2017","journal-title":"Br J Clin Pharmacol"},{"key":"R7-20260507","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/bcp.12614","article-title":"CYP2B6*6 allele and age substantially reduce steady-state ketamine clearance in chronic pain patients: Impact on adverse effects","volume":"80","author":"Li","year":"2015","journal-title":"Br J Clin Pharmacol"},{"key":"R8-20260507","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S0025-6196(11)60750-7","article-title":"Opioid metabolism","volume":"84","author":"Smith","year":"2009","journal-title":"Mayo Clin Proc"},{"key":"R9-20260507","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.clon.2011.04.015","article-title":"Evolving knowledge of opioid genetics in cancer pain","volume":"23","author":"Droney","year":"2011","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"R10-20260507","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1038\/sj.tpj.6500327","article-title":"Clinical response to morphine in cancer patients and genetic variation in candidate genes","volume":"5","author":"Ross","year":"2005","journal-title":"Pharmacogenomics J"},{"key":"R11-20260507","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.eujps.2011.08.022","article-title":"Elucidation of mu-opioid gene structure: How genetics can help predict responses to opioids","volume":"5","author":"Diatchenko","year":"2011","journal-title":"Eur J Pain Suppl"},{"key":"R12-20260507","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1111\/j.1399-6576.2004.00517.x","article-title":"The 118 A>G polymorphism in the human mu-opioid receptor gene may increase morphine requirements in patients with pain caused by malignant disease","volume":"48","author":"Klepstad","year":"2004","journal-title":"Acta Anaesthesiol Scand"},{"key":"R13-20260507","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1007\/s00228-013-1523-7","article-title":"Genetic variability at COMT but not at OPRM1 and UGT2B7 loci modulates morphine analgesic response in acute postoperative pain","volume":"69","author":"De Gregori","year":"2013","journal-title":"Eur J Clin Pharmacol"},{"key":"R14-20260507","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.pain.2006.10.023","article-title":"Exploring joint effects of genes and the clinical efficacy of morphine for cancer pain: OPRM1 and COMT gene","volume":"130","author":"Reyes-Gibby","year":"2007","journal-title":"Pain"},{"key":"R15-20260507","doi-asserted-by":"crossref","first-page":"64.","DOI":"10.1186\/1744-8069-4-64","article-title":"Genetic variation in the catechol-O-methyltransferase (COMT) gene and morphine requirements in cancer patients with pain","volume":"4","author":"Rakv\u00e5g","year":"2008","journal-title":"Mol Pain"},{"key":"R16-20260507","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1002\/cncr.23292","article-title":"Genetic variation and response to morphine in cancer patients","volume":"112","author":"Ross","year":"2008","journal-title":"Cancer"},{"key":"R17-20260507","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1111\/j.1742-7843.2009.00378.x","article-title":"The hypoalgesic effect of oxycodone in human experimental pain models in relation to the CYP2D6 oxidation polymorphism","volume":"104","author":"Zwisler","year":"2009","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"R18-20260507","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1111\/j.1476-5381.2010.00709.x","article-title":"Genetic polymorphisms and drug interactions modulating CYP2D6 and CYP3A activities have a major effect on oxycodone analgesic efficacy and safety","volume":"160","author":"Samer","year":"2010","journal-title":"Br J Pharmacol"},{"key":"R19-20260507","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/fcp.12128","article-title":"The genetic influences on oxycodone response characteristics in human experimental pain","volume":"29","author":"Olesen","year":"2015","journal-title":"Fundam Clin Pharmacol"},{"key":"R20-20260507","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ejps.2016.02.021","article-title":"Modelling the PKPD of oxycodone in experimental pain \u2013 Impact of opioid receptor polymorphisms","volume":"86","author":"Olsen","year":"2016","journal-title":"Eur J Pharm Sci"},{"key":"R21-20260507","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1111\/j.1476-5381.2010.00673.x","article-title":"The effects of CYP2D6 and CYP3A activities on the pharmacokinetics of immediate release oxycodone","volume":"160","author":"Samer","year":"2010","journal-title":"Br J Pharmacol"},{"key":"R22-20260507","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1177\/039463201102400417","article-title":"Micro opioid receptor A118G polymorphism and post-operative pain: Opioids\u2019 effects on heterozygous patients","volume":"24","author":"De Capraris","year":"2011","journal-title":"Int J Immunopathol Pharmacol"},{"key":"R23-20260507","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1038\/npp.2014.272","article-title":"Effects of the Mu opioid receptor polymorphism (OPRM1 A118G) on pain regulation, placebo effects and associated personality trait measures","volume":"40","author":"Peci\u00f1a","year":"2015","journal-title":"Neuropsychopharmacology"},{"key":"R24-20260507","doi-asserted-by":"crossref","first-page":"181","DOI":"10.2217\/pgs-2019-0141","article-title":"OPRM1 and COMT polymorphisms: Implications on postoperative acute, chronic and experimental pain after cardiac surgery","volume":"21","author":"Matic","year":"2020","journal-title":"Pharmacogenomics"},{"key":"R25-20260507","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/bcpt.13141","article-title":"Polymorphisms associated with fentanyl pharmacokinetics, pharmacodynamics and adverse effects","volume":"124","author":"Saiz-Rodr\u00edguez","year":"2019","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"R26-20260507","doi-asserted-by":"crossref","first-page":"e86","DOI":"10.1016\/j.clinthera.2021.03.005","article-title":"Influence of genetic polymorphisms on the response to tramadol, ibuprofen, and the combination in patients with moderate to severe pain after dental surgery","volume":"43","author":"Saiz-Rodr\u00edguez","year":"2021","journal-title":"Clin Ther"},{"key":"R27-20260507","doi-asserted-by":"crossref","first-page":"663","DOI":"10.2217\/pgs-2020-0026","article-title":"Involvement of CYP2D6 and CYP2B6 on tramadol pharmacokinetics","volume":"21","author":"Saiz-Rodr\u00edguez","year":"2020","journal-title":"Pharmacogenomics"},{"key":"R28-20260507","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/bcpt.12757","article-title":"Genetic influences of OPRM1, OPRD1 and COMT on morphine analgesia in a multi-modal, multi-tissue human experimental pain model","volume":"121","author":"Nielsen","year":"2017","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"R29-20260507","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1097\/j.pain.0000000000001750","article-title":"A functional polymorphism in the ATP-binding cassette B1 transporter predicts pharmacologic response to combination of nortriptyline and morphine in neuropathic pain patients","volume":"161","author":"Benavides","year":"2020","journal-title":"Pain"},{"key":"R30-20260507","doi-asserted-by":"crossref","first-page":"361","DOI":"10.2147\/PGPM.S198654","article-title":"OPRM1 A118G polymorphisms and its role in opioid addiction: Implication on severity and treatment approaches. In: Pharmacogenomics and Personalized Medicine. Vol. 12. Dove Medical Press Ltd.","volume":"12","author":"Taqi","year":"2019","journal-title":"Pharmacogenomics Personalized Medicine"},{"key":"R31-20260507","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.1016\/j.jfda.2013.09.036","article-title":"Pharmacogenomics study in a Taiwan methadone maintenance cohort","volume":"21","author":"Wang","year":"2013","journal-title":"J Food Drug Anal"},{"key":"R32-20260507","doi-asserted-by":"crossref","first-page":"741","DOI":"10.2217\/pgs-2018-0017","article-title":"The impact of OPRM1\u2019s genetic polymorphisms on methadone maintenance treatment in opioid addicts: A systematic review","volume":"19","author":"Oueslati","year":"2018","journal-title":"Pharmacogenomics"},{"key":"R33-20260507","doi-asserted-by":"crossref","first-page":"331","DOI":"10.2147\/JPR.S42040","article-title":"Consequences of the 118A>G polymorphism in the OPRM1 gene: Translation from bench to bedside?","volume":"6","author":"Mura","year":"2013","journal-title":"J Pain Res"},{"key":"R34-20260507","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1007\/s12031-018-1123-1","article-title":"Implication of OPRM1 A118G polymorphism in opioids addicts in Pakistan: In vitro and in silico analysis","volume":"65","author":"Ahmed","year":"2018","journal-title":"J Mol Neurosci"},{"key":"R35-20260507","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/s41397-019-0131-z","article-title":"OPRM1, OPRK1, and COMT genetic polymorphisms associated with opioid effects on experimental pain: A randomized, double-blind, placebo-controlled study","volume":"20","author":"Ho","year":"2020","journal-title":"Pharmacogenomics J"},{"key":"R36-20260507","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/clpt.2011.287","article-title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype","volume":"91","author":"Crews","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"R37-20260507","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1097\/00000542-200503000-00011","article-title":"The impact of pharmacogenomics on postoperative nausea and vomiting: Do CYP2D6 allele copy number and polymorphisms affect the success or failure of ondansetron prophylaxis?","volume":"102","author":"Candiotti","year":"2005","journal-title":"Anesthesiology"},{"key":"R38-20260507","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.pain.2009.03.023","article-title":"Can extremely low or high morphine formation from codeine be predicted prior to therapy initiation?","volume":"144","author":"L\u00f6tsch","year":"2009","journal-title":"Pain"},{"key":"R39-20260507","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/sj.clpt.6100152","article-title":"Concentrations of tramadol and O-desmethyltramadol enantiomers in different CYP2D6 genotypes","volume":"82","author":"Stamer","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"R40-20260507","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.phrs.2006.11.003","article-title":"Pharmacokinetics of tramadol enantiomers and their respective phase I metabolites in relation to CYP2D6 phenotype","volume":"55","author":"Garc\u00eda-Quetglas","year":"2007","journal-title":"Pharmacol Res"},{"key":"R41-20260507","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.forsciint.2014.03.003","article-title":"Pharmacogenetic aspects of tramadol pharmacokinetics and pharmacodynamics after a single oral dose","volume":"238","author":"Bastami","year":"2014","journal-title":"Forensic Sci Int"},{"key":"R42-20260507","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S0304-3959(03)00212-4","article-title":"Impact of CYP2D6 genotype on postoperative tramadol analgesia","volume":"105","author":"Stamer","year":"2003","journal-title":"Pain"},{"key":"R43-20260507","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1007\/s00228-006-0191-2","article-title":"Effect of the CYP2D6*10 C188T polymorphism on postoperative tramadol analgesia in a Chinese population","volume":"62","author":"Wang","year":"2006","journal-title":"Eur J Clin Pharmacol"},{"key":"R44-20260507","first-page":"179","article-title":"CYP2D6 genotype can help to predict effectiveness and safety during opioid treatment for chronic low back pain: Results from a retrospective study in an Italian cohort","volume":"11","author":"Dagostino","year":"2018","journal-title":"Pharmgenomics Pers Med"},{"key":"R45-20260507","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1097\/JCP.0b013e318160f827","article-title":"Effects of the CYP2D6 gene duplication on the pharmacokinetics and pharmacodynamics of tramadol","volume":"28","author":"Kirchheiner","year":"2008","journal-title":"J Clin Psychopharmacol"},{"key":"R46-20260507","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/clpt.2011.34","article-title":"Pharmacogenetics: From bench to byte \u2013 An update of guidelines","volume":"89","author":"Swen","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"R47-20260507","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1097\/FPC.0000000000000057","article-title":"PharmGKB summary: Tramadol pathway","volume":"24","author":"Gong","year":"2014","journal-title":"Pharmacogenet Genomics"},{"key":"R48-20260507","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2217\/pgs.12.187","article-title":"CYP3A4*22: Promising newly identified CYP3A4 variant allele for personalizing pharmacotherapy","volume":"14","author":"Elens","year":"2013","journal-title":"Pharmacogenomics"},{"key":"R49-20260507","doi-asserted-by":"crossref","first-page":"3316","DOI":"10.1158\/1078-0432.CCR-12-3786","article-title":"CYP3A4*22 genotype and systemic exposure affect paclitaxel-induced neurotoxicity","volume":"19","author":"de Graan","year":"2013","journal-title":"Clin Cancer Res"},{"key":"R50-20260507","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/s41397-019-0103-3","article-title":"Influence of CYP2B6 activity score on the pharmacokinetics and safety of single dose efavirenz in healthy volunteers","volume":"20","author":"Zubiaur","year":"2020","journal-title":"Pharmacogenomics J"},{"key":"R51-20260507","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/fcp.12168","article-title":"Impact of fraction unbound, CYP3A, and CYP2D6 in vivo activities, and other potential covariates to the clearance of tramadol enantiomers in patients with neuropathic pain","volume":"30","author":"de Moraes","year":"2016","journal-title":"Fundam Clin Pharmacol"},{"key":"R52-20260507","doi-asserted-by":"crossref","first-page":"e00419.","DOI":"10.1002\/prp2.419","article-title":"Enantioselective pharmacokinetics of tramadol and its three main metabolites; impact of CYP2D6, CYP2B6, and CYP3A4 genotype","volume":"6","author":"Haage","year":"2018","journal-title":"Pharmacol Res Perspect"},{"key":"R53-20260507","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1097\/j.pain.0000000000000662","article-title":"Loss-of-function polymorphisms in the organic cation transporter OCT1 are associated with reduced postoperative tramadol consumption","volume":"157","author":"Stamer","year":"2016","journal-title":"Pain"}],"container-title":["Journal of Advanced Pharmaceutical Technology &amp; Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/JAPTR.JAPTR_69_24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T16:26:34Z","timestamp":1786724794000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/JAPTR.JAPTR_69_24"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":53,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.4103\/japtr.japtr_69_24","relation":{},"ISSN":["2231-4040","0976-2094"],"issn-type":[{"value":"2231-4040","type":"print"},{"value":"0976-2094","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"2024-02-19","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-06-10","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}